VEGF-induced effects on proliferation, migration and tight junctions are restored by ranibizumab (Lucentis) in microvascular retinal endothelial cells

British Journal of Ophthalmology

Volumn 92, Issue 6, 2008, Pages 839-843

  Deissler, H ^a   Lang, S ^a   Lang, G E ^a  

^a UNIVERSITY OF ULM MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLAUDIN 1; CLAUDIN 5; OCCLUDIN; PROTEIN ZO1; RANIBIZUMAB; VASCULOTROPIN 121; VASCULOTROPIN 165;

ANIMAL CELL; ARTICLE; CELL IMMORTALIZATION; CELL MEMBRANE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RETINA BLOOD VESSEL; TIGHT JUNCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; CATTLE; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; IMMUNOHISTOCHEMISTRY; MEMBRANE PROTEINS; MICROCIRCULATION; PHOSPHOPROTEINS; RETINA; TIGHT JUNCTIONS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 45249116797     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2007.135640     Document Type: Article

References (29)

1. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-7.
2. Boulton M, Foreman D, Williams G, et al. VEGF localisation in diabetic retinopathy. Br J Ophthalmol 1998;82:561-8.
3. Watanabe D, Suzuma K, Suzuma I, et al. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2005;139:476- 81.
4. Malik RA, Li C, Aziz W, et al. Elevated plasma CD105 and vitreous VEGF levels in diabetic retinopathy. J Cell Mol Med 2005;9:692-7.
5. Caldwell RB, Bartoli M, Behzadian MA, et al. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 2003;19:442-55.
6. Qaum T, Xu Q, Joussen AM, et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 2001;42:2408-13.
7. Behzadian MA, Windsor LJ, Ghaly N, et al. VEGF-induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor. FASEB J 2003;17:752-4.
8. Caldwell RB, Bartoli M, Behzadian MA, et al. Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. Curr Drug Targets 2005;6:511-24.
9. Lutty GA, Mathews MK, Merges C, et al. Adenosine stimulates canine retinal microvascular endothelial cell migration and tube formation. Curr Eye Res 1998;17:594-607.
10. Deissler H, Deissler H, Lang GK, et al. Generation and characterization of iBREC: novel hTERT-immortalized bovine retinal endothelial cells. Int J Mol Med 2005;16:65-70.
11. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611.
12. 121 and regulates endothelial cell migration and sprouting. J Biol Chem 2007;282:24049-56.
13. Antonetti DA, Barber AJ, Hollinger LA, et al. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occludens 1. J Biol Chem 1999;274:23463-7.
14. Harhaj NS, Felinski EA, Wolpert EB, et al. VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability. Invest Ophthalmol Vis Sci 2006;47:5106- 15.
15. Bazzoni G. Endothelial tight junctions: permeable barriers of the vessel wall. Thromb Haemost 2006;95:36-42.
16. Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2001;2:285-93.
17. Vinores SA. Technology evaluation: pegaptanib, Eyetech/Pfizer. Curr Opin Mol Ther 2003;5:673-9.
18. Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26:859-70.
19. Deissler H, Deissler H, Lang GK, et al. TGFβ induces transdifferentiation of iBREC to αSMA-expressing cells. Int J Mol Med 2006;18:577-82.
20. Deissler H, Kuhn EM, Lang GE, et al. Tetraspanin CD9 is involved in the migration of retinal microvascular endothelial cells. Int J Mol Med 2007;20:643-52.
21. Lowe J, Araujo J, Yang J, et al. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res 2007;85:425-30.
22. Spitzer MS, Yoeruek E, Sierra A, et al. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. Graefes Arch Clin Exp Ophthalmol 2007;245:1837-42.
23. Spitzer MS, Wallenfels-Thilo B, Sierra A, et al. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol 2006;90:1316-21.
24. Peters S, Julien S, Heiduschka P, et al. Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells. Br J Ophthalmol 2007;91:827-31.
25. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
26. Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006;142:961-9.
27. Harhaj NS, Antonetti DA. Regulation of tight junctions and loss of barrier function in pathophysiology. Int J Biochem Cell Biol 2004;36:1206-37.
28. Wong V. Phosphorylation of occludin correlates with occludin localization and funciton at the tight junction. Am J Physiol 1997;273:C1859-67.
29. Sakakibara A, Furuse M, Saitou M, et al. Possible involvement of phosphorylation of occludin in tight junction formation. J Cell Biol 1997;137:1393-401.